{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:21:34Z","timestamp":1777429294616,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,6,3]],"date-time":"2018-06-03T00:00:00Z","timestamp":1527984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00228-018-2496-3","type":"journal-article","created":{"date-parts":[[2018,6,3]],"date-time":"2018-06-03T04:35:35Z","timestamp":1528000535000},"page":"1181-1184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tamoxifen and the risk of Parkinsonism: a case\/non-case study"],"prefix":"10.1007","volume":"74","author":[{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzin","family":"Khosrow-Khavar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"de Germay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Renoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Benevent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,3]]},"reference":[{"key":"2496_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1472-8206.1994.tb00808.x","volume":"8","author":"JL Montastruc","year":"1994","unstructured":"Montastruc JL, Llau ME, Rascol O, Senard JM (1994) Drug-induced Parkinsonism: a review. Fundam Clin Pharmacol 8:293\u2013306","journal-title":"Fundam Clin Pharmacol"},{"key":"2496_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2515\/therapie:2004021","volume":"59","author":"N Nguyen","year":"2004","unstructured":"Nguyen N, Pradel V, Micallef J, Montastruc JL, Blin O (2004) Drug-induced parkinson syndromes. Therapie 59:105\u2013112","journal-title":"Therapie"},{"key":"2496_CR3","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/mds.23828","volume":"26","author":"E Bondon-Guitton","year":"2011","unstructured":"Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL (2011) Drug-induced Parkinsonism: a review of 17 years\u2019 experience in a regional pharmacovigilance center in France. Mov Disord 26:2226\u20132231","journal-title":"Mov Disord"},{"key":"2496_CR4","first-page":"1237","volume-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"C Isaacs","year":"2018","unstructured":"Isaacs C, Wellstein A, Riegel A (2018) Hormones and related agents in the therapy of cancer. In: Brunton L, Hilal-Dandan R, Knollmann BC (eds) Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics, 13th edn. Mc Graw Hill Medical, New York, pp 1237\u20131247","edition":"13"},{"key":"2496_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2377-10-23","volume":"10","author":"JC Latourelle","year":"2010","unstructured":"Latourelle JC, Dybdahl M, Destefano AL, Myers RH, Lash TL (2010) Risk of Parkinson\u2019s disease after tamoxifen treatment. BMC Neurol 10:23","journal-title":"BMC Neurol"},{"key":"2496_CR6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.4048\/jbc.2017.20.4.356","volume":"20","author":"CT Hong","year":"2017","unstructured":"Hong CT, Chan L, Hu CJ, Lin CM, Hsu CY, Lin MC (2017) Tamoxifen and the risk of Parkinson\u2019s disease in female patients with breast cancer in Asian people: a nationwide population-based study. J Breast Cancer 20:356\u2013360","journal-title":"J Breast Cancer"},{"key":"2496_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00228-017-2341-0","volume":"74","author":"HF Lin","year":"2018","unstructured":"Lin HF, Liao KF, Chang CM, Lin CL, Lai SW (2018) Tamoxifen usage correlates with increased risk of Parkinson\u2019s disease in older women with breast cancer: a case-control study in Taiwan. Eur J Clin Pharmacol 74:99\u2013107","journal-title":"Eur J Clin Pharmacol"},{"key":"2496_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.lfs.2011.03.010","volume":"88","author":"AM Baraka","year":"2011","unstructured":"Baraka AM, Korish AA, Soliman GA, Kamal H (2011) The possible role of estrogen and selective estrogen receptor modulators in a rat model of Parkinson\u2019s disease. Life Sci 88:879\u2013885","journal-title":"Life Sci"},{"key":"2496_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0306-4522(01)00014-8","volume":"103","author":"X Gao","year":"2001","unstructured":"Gao X, Dulzen DE (2001) Tamoxifen abolishes estrogen\u2019s neuroprotective effect upon metamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 103:385\u2013394","journal-title":"Neuroscience"},{"key":"2496_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905\u2013908","journal-title":"Br J Clin Pharmacol"},{"key":"2496_CR11","doi-asserted-by":"publisher","unstructured":"Faillie JL (2017) Case-non case studies: principles, methods, bias and interpretation. Therapie. \n                    https:\/\/doi.org\/10.1016\/j.therap.2017.08.006","DOI":"10.1016\/j.therap.2017.08.006"},{"key":"2496_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.therap.2016.09.020","volume":"72","author":"J Bezin","year":"2017","unstructured":"Bezin J, Bosco-Levy P, Pariente A (2017) False-positive results in pharmacoepidemiology and pharmacovigilance. Therapie 72:415\u2013420","journal-title":"Therapie"},{"key":"2496_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1472-8206.2007.00552.x","volume":"22","author":"A Bate","year":"2008","unstructured":"Bate A, Lindquist M, Edwards IR (2008) The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 22:127\u2013140","journal-title":"Fundam Clin Pharmacol"},{"key":"2496_CR14","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255\u20131259","journal-title":"Lancet"},{"key":"2496_CR15","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.2337\/dc12-0788","volume":"35","author":"S Suissa","year":"2012","unstructured":"Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35:2665\u20132673","journal-title":"Diabetes Care"},{"key":"2496_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir AW (2006) Under-reporting od Adverse Drug Reactions. A systematic review. Drug Saf 29:385\u2013398","journal-title":"Drug Saf"},{"key":"2496_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1046\/j.1365-2125.1999.00881.x","volume":"47","author":"C Pierfitte","year":"1999","unstructured":"Pierfitte C, B\u00e9gaud B, Lagnaoui R, Moore NDI (1999) Reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol 47:329\u2013331","journal-title":"Br J Clin Pharmacol"},{"key":"2496_CR18","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/BF03261981","volume":"35","author":"A Pariente","year":"2012","unstructured":"Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salam\u00e9 G, Fourrier-Reglat A, Haramburu F, B\u00e9gaud B, Moore N, Association Fran\u00e7aise des (2012) Centres R\u00e9gionaux de pharmacovigilance (CRPV). Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf 35:855\u2013864","journal-title":"Drug Saf"},{"key":"2496_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40264-013-0063-5","volume":"36","author":"F Salvo","year":"2013","unstructured":"Salvo F, Leborgne F, Thiessard F, Moore N, B\u00e9gaud B, Pariente A (2013) A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France. Drug Saf 36:565\u2013572","journal-title":"Drug Saf"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2496-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2496-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2496-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T23:25:39Z","timestamp":1559517939000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2496-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,3]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["2496"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2496-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,3]]},"assertion":[{"value":"13 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None, except for Professor Olivier Rascol who was consultant and\/or member of advisory boards for AbbVie, Adamas, Acorda, Addex, AlzProtect, Apopharma, Astrazeneca, Bial, Biogen, Britannia, Clevexel, INC Reasearch, Lundbeck, Lupin, Merck, MundiPharma, Neuratris, Neuroderm, Novartis, Oxford Biomedica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Sanofi, Servier, Sunovion, Takeda, Teva, UCB, XenoPort, and Zambon and received grants from Agence Nationale de la Recherche (ANR), CHU de Toulouse, France-Parkinson, INSERM-DHOS Recherche Clinique Translationnelle, MJFox Foundation, Programme Hospitalier de Recherche Clinique, and European Commission (FP7, H2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}